---
title: "Mounjaro (tirzepatide), all indications: Dosing and administration questions"
description: "Dosing and administration questions on Mounjaro (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Administration. Questions: How should a missed Mounjaro dose be handled? Can the Mounjaro injection day be changed? How and where is Mounjaro injected? Can Mounjaro be taken with or without food? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/mounjaro/dosing-and-administration"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Mounjaro (tirzepatide), all indications: Dosing and administration questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Mounjaro](https://uspl.lilly.com/mounjaro/mounjaro.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/mounjaro--type-2-diabetes)

## Dosing

<a id="mounjaro-missed-dose"></a>

### How should a missed Mounjaro dose be handled?

> “If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=If%20a%20dose%20is%20missed%2C,regular%20once%20weekly%20dosing%20schedule.)

<a id="mounjaro-injection-day"></a>

### Can the Mounjaro injection day be changed?

> “The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=The%20day%20of%20weekly%20administration,least%203%20days%20%2872%20hours%29.)

## Administration

<a id="mounjaro-how-to-inject"></a>

### How and where is Mounjaro injected?

> “Administer MOUNJARO once weekly, any time of day, with or without meals.
> Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm.
> Rotate injection sites with each dose.
> Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Administer%20MOUNJARO%20once%20weekly%2C%20any,matter%20or%20discoloration%20is%20seen.)

> “Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Similar%20exposure%20was%20achieved%20with,abdomen%2C%20thigh%2C%20or%20upper%20arm.)

<a id="mounjaro-food"></a>

### Can Mounjaro be taken with or without food?

> “Administer MOUNJARO once weekly, any time of day, with or without meals.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Administer%20MOUNJARO%20once%20weekly%2C%20any%20time%20of%20day%2C%20with%20or%20without%20meals.)

<a id="mounjaro-pens-vials-kwikpen"></a>

### What forms does Mounjaro come in: single-dose pen, vial, or KwikPen?

> “Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens, each available in the following strengths. The multi-dose vials and single-patient-use KwikPen each contain 4 doses:
>
> Single-dose Pen or Vial
> 2.5 mg/0.5 mL
> 5 mg/0.5 mL
> 7.5 mg/0.5 mL
> 10 mg/0.5 mL
> 12.5 mg/0.5 mL
> 15 mg/0.5 mL
> Multi-dose Vial (4 doses per vial)
> Dose per Injection	Total Strength per Total Volume	Strength per mL
> 2.5 mg/0.6 mL	10 mg/2.4 mL	4.17 mg/mL
> 5 mg/0.6 mL	20 mg/2.4 mL	8.33 mg/mL
> 7.5 mg/0.6 mL	30 mg/2.4 mL	12.5 mg/mL
> 10 mg/0.6 mL	40 mg/2.4 mL	16.7 mg/mL
> 12.5 mg/0.6 mL	50 mg/2.4 mL	20.8 mg/mL
> 15 mg/0.6 mL	60 mg/2.4 mL	25 mg/mL
> Single-Patient-Use KwikPen (4 doses per KwikPen)
> Dose per Injection	Total Strength per Total Volume	Strength per mL
> 2.5 mg	10 mg/2.4 mL	4.17 mg/mL
> 5 mg	20 mg/2.4 mL	8.33 mg/mL
> 7.5 mg	30 mg/2.4 mL	12.5 mg/mL
> 10 mg	40 mg/2.4 mL	16.7 mg/mL
> 12.5 mg	50 mg/2.4 mL	20.8 mg/mL
> 15 mg	60 mg/2.4 mL	25 mg/mL”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Injection%3A%20Clear%2C%20colorless%20to%20slightly,25%20mg%2FmL)

> “Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Inform%20patients%20and%20their%20caregiver%28s%29,for%20the%20newly%20prescribed%20presentation.)

> “MOUNJARO KwikPen is not recommended for self-administration by pediatric patients.
> MOUNJARO KwikPen is not recommended for self-administration by those who are visually impaired.
> Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=MOUNJARO%20KwikPen%20is%20not%20recommended,and%20needle%20for%20each%20injection.)

> “Each single-patient-use KwikPen contains additional volume to allow for device priming.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Each%20single%2Dpatient%2Duse%20KwikPen%20contains%20additional%20volume%20to%20allow%20for%20device%20priming.)

> “Never share MOUNJARO KwikPen between patients, even if the pen needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.”

Source: [MOUNJARO: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/mounjaro/mounjaro.html#pi:~:text=Never%20share%20MOUNJARO%20KwikPen%20between,for%20transmission%20of%20blood%2Dborne%20pathogens.)

## Related pages
- [Medical information: Mounjaro (tirzepatide): All indications](https://www.evicenter.com/medical-information/mounjaro)
- [Indication](https://www.evicenter.com/medical-information/mounjaro/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/mounjaro/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/mounjaro/safety)
- [Specific populations](https://www.evicenter.com/medical-information/mounjaro/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/mounjaro/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/mounjaro/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/mounjaro/access-and-coverage)
